Noventure and Pierre Fabre Pharma Italy, announce that they have entered into an agreement in which Pierre Fabre will distribute Noventure’s Aprotecol® in Italy.
Aprotecol is a Class IIa CE marked medical device used to treat and prevent bloating and intestinal colic in infants and young children. Abdominal tension and colic are frequent in infants and children. This may be caused by different factors, including leaky intestinal mucosa1 or the growth of gas-producing bacteria in the intestines.
Aprotecol was designed in line with the latest science on the underlying causes of colic in infants, providing an effective reinforcement of the mucosal barrier and a re-balancing of the intestinal flora.
Aprotecol is available as an oily suspension for oral use.
Colic is a common condition worldwide: 20% of infants younger than three months develop infant colic. Raising colicky babies or children with bloating and abdominal pain can be a common source of frustration and distress for parents and a costly problem for health services.
Luciano Conde, CEO of Noventure said: “Aprotecol is an innovative product that will help to improve the quality of life of young patients across Italy affected by colic and bloating as well as their parents. We firmly believe that partnering with Pierre Fabre, whose commitment to children’s healthcare is recognized worldwide, represents a great opportunity for Noventure to further disseminate its innovative barrier technology.”
Charles-Henri Bodin, general manager of Pierre Fabre Pharma Italy said: “Aprotecol is a great opportunity for Pierre Fabre to reinforce its position in pediatrics in Italy. Our teams are prepared and highly motivated to offer Italian pediatricians this innovative solution to treat their young patients.”
Pierre Fabre Pharma Italy anticipates launching Aprotecol in January 2018.
Noventure’s business model is based on offering exclusive commercial rights for selected regions to its distribution partners. Aprotecol is being partnered by Noventure worldwide.
